Lantern Research Development from 2010 to 2026

LTRN Stock  USD 3.15  0.04  1.29%   
Lantern Pharma Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to grow to about 19.5 M this year. During the period from 2010 to 2026, Lantern Pharma Research Development quarterly data regression pattern had sample variance of 48.9 T and median of  572,095. View All Fundamentals
 
Research Development  
First Reported
2019-03-31
Previous Quarter
3.1 M
Current Value
2.4 M
Quarterly Volatility
1.4 M
 
Covid
 
Interest Hikes
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 K, Interest Expense of 246.8 K or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.53. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
Build AI portfolio with Lantern Stock
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
Evaluating Lantern Pharma's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lantern Pharma's fundamental strength.

Latest Lantern Pharma's Research Development Growth Pattern

Below is the plot of the Research Development of Lantern Pharma over the last few years. It is Lantern Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Lantern Research Development Regression Statistics

Arithmetic Mean5,326,772
Geometric Mean1,916,207
Coefficient Of Variation131.28
Mean Deviation5,911,673
Median572,095
Standard Deviation6,992,884
Sample Variance48.9T
Range18.9M
R-Value0.86
Mean Square Error13.9T
R-Squared0.73
Significance0.000012
Slope1,185,734
Total Sum of Squares782.4T

Lantern Research Development History

202619.5 M
202518.5 M
202416.1 M
202311.9 M
20228.6 M
20217.6 M
20202.2 M

About Lantern Pharma Financial Statements

Lantern Pharma investors utilize fundamental indicators, such as Research Development, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development18.5 M19.5 M

Pair Trading with Lantern Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lantern Stock

  0.63IMNN Imunon IncPairCorr
  0.61IPHA Innate PharmaPairCorr
  0.71MBIO Mustang BioPairCorr

Moving against Lantern Stock

  0.46AEON AEON BiopharmaPairCorr
  0.38MOLN Molecular PartnersPairCorr
The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.
The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Lantern diversify its offerings? Factors like these will boost the valuation of Lantern Pharma. Expected growth trajectory for Lantern significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lantern Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.75)
Return On Assets
(0.56)
Return On Equity
(1.05)
Understanding Lantern Pharma requires distinguishing between market price and book value, where the latter reflects Lantern's accounting equity. The concept of intrinsic value—what Lantern Pharma's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lantern Pharma's price substantially above or below its fundamental value.
Understanding that Lantern Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lantern Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lantern Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.